These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 25388909)

  • 1. Indirect comparison between subcutaneous biologic agents in ankylosing spondylitis.
    Migliore A; Bizzi E; Bernardi M; Picchianti Diamanti A; Laganà B; Petrella L
    Clin Drug Investig; 2015 Jan; 35(1):23-9. PubMed ID: 25388909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indirect comparison of the effects of anti-TNF biological agents in patients with ankylosing spondylitis by means of a mixed treatment comparison performed on efficacy data from published randomised, controlled trials.
    Migliore A; Broccoli S; Bizzi E; Laganà B
    J Med Econ; 2012; 15(3):473-80. PubMed ID: 22335398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect comparison of anti-TNF-α agents for active ankylosing spondylitis: mixed treatment comparison of randomized controlled trials.
    Shu T; Chen GH; Rong L; Feng F; Yang B; Chen R; Wang J
    Clin Exp Rheumatol; 2013; 31(5):717-22. PubMed ID: 23899710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Efficacy and Acceptability of Anti-TNF-Alpha Therapy in Ankylosing Spondylitis: A Mixed-Treatments Comparison.
    Wang Y; Wang H; Jiang J; Zhao D; Liu Y
    Cell Physiol Biochem; 2016; 39(5):1679-1694. PubMed ID: 27643888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal.
    Armstrong N; Joore M; van Asselt T; Misso K; Manning N; Tomini F; Kleijnen J; Riemsma R
    Pharmacoeconomics; 2013 May; 31(5):415-25. PubMed ID: 23580355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial.
    Bao C; Huang F; Khan MA; Fei K; Wu Z; Han C; Hsia EC
    Rheumatology (Oxford); 2014 Sep; 53(9):1654-63. PubMed ID: 24729398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Callhoff J; Sieper J; Weiß A; Zink A; Listing J
    Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Comparative Safety of TNF Inhibitors in Ankylosing Spondylitis-a Meta-Analysis Update of 14 Randomized Controlled Trials.
    Hou LQ; Jiang GX; Chen YF; Yang XM; Meng L; Xue M; Liu XG; Chen XC; Li X
    Clin Rev Allergy Immunol; 2018 Apr; 54(2):234-243. PubMed ID: 28717941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials.
    Gensler LS; Chakravarty SD; Cameron C; Peterson S; Spin P; Kafka S; Nair S; Deodhar A
    Clin Rheumatol; 2020 Oct; 39(10):2907-2917. PubMed ID: 32367407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect comparisons of the efficacy of biological agents in patients with active ankylosing spondylitis: a systematic review and meta-analysis.
    Ungprasert P; Erwin PJ; Koster MJ
    Clin Rheumatol; 2017 Jul; 36(7):1569-1577. PubMed ID: 28551823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in biologics for treating ankylosing spondylitis: the contribution of network meta-analysis.
    Migliore A; Gigliucci G; Integlia D; Isailovic N; Frediani B
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):56-64. PubMed ID: 33506892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis.
    Betts KA; Griffith J; Song Y; Mittal M; Joshi A; Wu EQ; Ganguli A
    Rheumatol Ther; 2016 Dec; 3(2):323-336. PubMed ID: 27747581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Challenge of Treating Early-Stage Rheumatoid Arthritis: The Contribution of Mixed Treatment Comparison to Choosing Appropriate Biologic Agents.
    Migliore A; Bizzi E; Petrella L; Bruzzese V; Cassol M; Integlia D
    BioDrugs; 2016 Apr; 30(2):105-15. PubMed ID: 26905069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis.
    Baji P; Péntek M; Szántó S; Géher P; Gulácsi L; Balogh O; Brodszky V
    Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S45-52. PubMed ID: 24832835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    van der Heijde D; Kivitz A; Schiff MH; Sieper J; Dijkmans BA; Braun J; Dougados M; Reveille JD; Wong RL; Kupper H; Davis JC;
    Arthritis Rheum; 2006 Jul; 54(7):2136-46. PubMed ID: 16802350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review and network meta-analysis of current and investigational treatments for active ankylosing spondylitis.
    Deodhar A; Chakravarty SD; Cameron C; Peterson S; Hensman R; Fogarty S; Spin P; Kafka S; Nair S; Gensler LS
    Clin Rheumatol; 2020 Aug; 39(8):2307-2315. PubMed ID: 32107666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG; Halilovic J; Stan-Ugbene O
    Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Oldfield V; Plosker GL
    BioDrugs; 2009; 23(2):125-35. PubMed ID: 19489653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Jain M; Jugl SM
    J Med Econ; 2019 Jan; 22(1):45-52. PubMed ID: 30346844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The safety and efficacy of golimumab in treatment of 25 patients with active ankylosing spondylitis].
    Ma H; Sun F; Zhang YM; Zhang H; Zhu J; Deng XH; Zhang JL; Huang F
    Zhonghua Nei Ke Za Zhi; 2017 Dec; 56(12):935-939. PubMed ID: 29202535
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.